ELVN Stock Summary and Trading Ideas (Enliven Therapeutics | NASDAQ:ELVN)

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.

As of January 14, 2026, ELVN stock price climbed to $26.05 with 1,037,801 million shares trading.

ELVN has a beta of 0.96, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.04 to the broad based SPY ETF.

ELVN has a market cap of $1.55 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ELVN has underperformed the market in the last year with a return of +18.0%, while SPY returned +20.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ELVN shares. However, ELVN has outperformed the market in the last 3 month and 2 week periods, returning +26.0% and +67.5%, while SPY returned +4.4% and +0.5%, respectively. This indicates ELVN has been having a stronger performance recently.

ELVN support price is $24.47 and resistance is $27.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.